Compare Novavax Inc (NVAX) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Rivian Automotive, Inc. — how do they compare? Novavax Inc trades at $12.73 (market cap $1.82B), while Rivian Automotive, Inc. trades at $13.97 (market cap $20.75B). The key difference: Rivian Automotive, Inc. is far larger — about 11.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Rivian Automotive, Inc. for 61 Days on average.
| NVAX | RIVN | |
|---|---|---|
Market Cap | $1.82B | $20.75B |
Volume | 6,198,505 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $22.45 |
52-Week Low | $6.22 | $12.50 |
Typical Hold Time | 59 Days | 61 Days |
Enterprise Value | $1.39B | $20.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Rivian Automotive (RIVN) trades at $13.96, down 2.65% amid bearish technical signals despite strong Q3 2026 delivery results. The company reported record production of 19,751 vehicles and deliveries of 19,248, beating estimates but maintaining unchanged guidance. Fundamentally, RIVN shows improving revenue growth ($5.39B in 2025) but continues significant losses (-$3.65B net income) with negative margins. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show 18 sell signals versus 2 buy signals.
Rivian's investment case balances strong delivery growth and R2 SUV ramp-up against persistent cash burn and competitive EV market pressures. The stock offers upside to analyst targets but faces execution risks in achieving profitability. Key catalysts include R2 production scaling and autonomy technology rollout, while main risks involve cash flow sustainability and intense industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
